O perational tolerance to allografts and cellular xenografts can be induced by the blockade of the surface molecules CD40/CD40L, CD28/CTLA4/B7, and intercellular adhesion molecule (ICAM)-1-3/leukotactic factor activity (LFA)-1 (1) (2) (3) . Tolerance induced by costimulation blockade has been shown to be due to deletion of antigen-specific T cells or induction of dominant tolerance mediated by regulatory T cells (Treg) (reviewed in [4, 5] ). Recently, the natural CD4 ϩ
CD25
ϩ Treg have been implicated in transplantation tolerance (reviewed in [4, 6] ). Natural Treg are efficient regulators of destructive autoimmune responses, inflammation, and T-cell homeostasis and their regulatory mechanism involves transforming growth factor (TGF)-␤, interleukin (IL)-10, and cytotoxic T lymphocyte-associated antigen (CTLA)-4 (7, 8) . It has been shown that these cells can both prevent naïve, nontolerant cells from rejecting transplanted grafts (9) and convey regulatory properties to naïve T cells, an activity originally termed infectious tolerance (10) . Natural Treg were originally described to be generated in the thymus (11, 12) . However, these cells can also be induced from CD4 ϩ
Ϫ precursors in peripheral lymphoid tissues using various tolerance induction protocols (13) (14) (15) (16) . Similarly, costimulation blockade has been used both in vivo and in vitro to induce alloantigen-specific Treg that can prevent graft rejection upon adoptive transfer to naïve recipients (17) (18) (19) . Treg involved in transplantation tolerance have in some cases been shown to require IL-10 for their functional activity but not in others (20) . We have previously obtained long-term graft survival in various allo-and xenograft trans-plant models by the combined treatment with anti-CD40L, anti-lymphocyte function-associated antigen (LFA)-1, and CTLA4 immunoglobulin (Ig) (1, (21) (22) (23) (24) . This study was undertaken to determine whether graft acceptance relies on natural regulatory CD4 ϩ
ϩ T cells and on IL-10 production by recipient T cells.
METHODS

Mice
Female BALB/c (H-2 d ) and C57BL/6 (H-2 b ) mice were purchased from M&B (Ry, Denmark) and B6.129S7-Rag1tm1Mom and IL-10 Ϫ/Ϫ on C57BL/6(H-2 b ) background were purchased from Jackson Laboratories (Bar Harbor, ME). Mice were between 6 and 12 weeks of age. Mice were housed in a specific pathogen-free (SPF) facility. IL-10
and Rag1 Ϫ/Ϫ mice were kept in sterile housing given access to irradiated food to inhibit the colonization of the mice with a bacterial flora which can lead to colitis in these mouse strains (25) . All experiments were performed according to the guidelines of the local ethical committee of The Swedish National Board for Laboratory Animals.
Reagents
CTLA4Ig, anti-LFA-1 (anti-CD11a) clone M17/5.2, anti-CD40L clone MR-1, rat IgG, hamster IgG, and human IgG isotype control antibodies were purchased from Bioexpress (West Lebanon, NH).
Heart Transplantation
Vascularized heterotopic heart transplantation from BALB/c donors to recipient C57BL/6, IL-10 Ϫ/Ϫ or Rag 1 Ϫ/Ϫ mice was performed with anastomosis to the vessels of the neck using a nonsuture cuff technique (26) . Graft survival was monitored by daily palpation. Rejection was defined as loss of palpable cardiac contractions. C57BL/6 mice were treated with 200 g anti-LFA-1, 500 g anti-CD40L, and 500 g CTLA4Ig (costimulation blockade) on the day of transplantation and every other day for six days. The grafts were harvested after 100 days. Three mice received a skin graft of donor type 50 days after transplantation and were harvested of their primary heart graft at 100 days after cardiac transplantation. IL-10 Ϫ/Ϫ mice were transplanted and treated with costimulation blockade. Rag1 Ϫ/Ϫ mice received a cardiac transplant 12-48 hr after reconstitution with either 10ϫ10
Ϫ T cells from C57BL/6 donors. These recipients were randomized to treatment with costimulation blockade or the same doses of the isotype control antibodies. One group of Rag1 Ϫ/Ϫ mice received a cardiac transplant 40 -45 days before reconstitution with 10ϫ10 6 CD4 ϩ cells from wild type or IL10 Ϫ/Ϫ mice. These mice received the same treatment as the other Rag1 Ϫ/Ϫ recipients but commencing after the cell reconstitution.
Skin Transplantation
Full thickness BALB/c mice ear skin was transplanted onto the dorsal thorax of C57BL/6 mice. Grafts were inspected daily for deterioration of quality and any signs of rejection. Rejection was defined as shrinkage to 10% of the original size, development of widespread ulceration of the graft, or a 90% loss of viable hair.
Histological Evaluation of Rejection
Paraffin-embedded transventricular tissue sections (5 m) were stained with elastic Van Giesen and hematoxylin/ eosin. A transplant pathologist (B.V.), blinded to treatment modality, reviewed the histological specimens. Signs of rejection/inflammation were graded by examining the extent of lymphocytic infiltrate and the anatomical localization of leukocytes as follows (27) : Grade 0; no rejection, Grade 1; mild, patchy lymphocytic infiltrate and fibrosis, Grade 2; moderate lymphocytic infiltrate and fibrosis, Grade 3; massive, diffuse infiltrate and fibrosis. The extent of rejection changes in all slides were also ranked and compared between the groups. Chronic vasculopathy was assessed by examining the proportion of diseased arteriola in one representative tissue section from each heart.
Histological Detection of Foxp3-Expressing Cells
Graft cryostat sections (5 m) were fixed with 4% paraformaldehyde and blocked with 1% bovine serum albumin (Sigma-Aldrich Inc., Sweden AB) and anti-FcRII/III (2.4G2) antibodies. Sections were thereafter stained with rat anti-CD45 (prepared in our lab) and in a second step fluorescein isothiocyanate (FITC)-conjugated goat antirat antibody (Jackson ImmunoResearch Europe, Soham, Cambridgeshire, UK), followed by blocking with 5% normal rat serum (SigmaAldrich, Inc., Sweden AB) and avidin/biotin block (Vector Laboratories Inc., Burlingame, CA) including 5% normal goat serum (Sigma-Aldrich) prior to staining with biotin conjugated rat anti-Foxp3 (E-Bioscience, Nordic Biosite, Täby, Sweden), and Cy3-conjugated streptavidin (Jackson ImmunoResearch). Fixation and blocking steps were performed for 15 min at 37°C and all antibody incubations for 45 min at 37°C. Stained sections were examined with a Zeiss Axiophot microscope equipped with epiflourescent optics and documented with a Hamamatsu ORCA1 camera and the Openlab software (Improvision, London, UK).
Enrichment of Cell Populations, CFSE Staining, and Cell Reconstitution
Single-cell suspensions were prepared from pooled spleens and lymph nodes. B cells were removed by panning on antimouse Ig coated plates. CD25 ϩ cells are almost exclusively found among CD4 ϩ T cells. Therefore, to enrich for CD4 ϩ
CD25
Ϫ CD103 Ϫ or CD4 ϩ CD25 Ϫ T cells, the pooled spleen and lymph node cells were incubated with biotinconjugated CD103 and/or biotin-conjugated CD25 antibodies (Pharmingen, San Diego, CA) followed by SA-microbeads (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) and separated using AutoMACS (Miltenyi Biotec). CD4
Ϫ T cells were subsequently isolated from the unbound cells using anti-CD4 conjugated magnetic microbeads and separation using AutoMACS (Miltenyi Biotec). This procedure yielded Ͼ95% pure CD4
Ϫ T cells. Total CD4 ϩ T cell populations were isolated using anti-CD4 conjugated magnetic microbeads (Miltenyi Biotec). This procedure yielded Ͼ95% pure CD4 ϩ T cells. The cells were counted and resuspended in sterile phosphatebuffered saline (PBS). Then 10ϫ10 6 Ϫ/Ϫ C57BL/6 recipient mice. For isolation of graft infiltrating cells, harvested grafts were first perfused with PBS, to avoid contamination of blood derived cells, and thereafter treated with collagenase type IV (1.6 mg/ml, 30 min, 37°C; Sigma-Aldrich) to release tissue-infiltrating cells.
Antibodies and Flow Cytometry
The following antibodies were used for flow cytometric analysis of cell purity and Foxp3 expression: Cy-5 conjugated anti-CD4, anti-FcRII/III (2.4G2, prepared in our laboratory), 7-amino-actinomycin D (7AAD, Sigma-Aldrich), FITCconjugated anti-CD25, FITC-conjugated anti-T-cell receptor (TcR)-␤, antigen-presenting cell (APC)-conjugated anti-CD4, PE-conjugated isotype control (Pharmingen, San Diego, CA), PE-conjugated anti-Foxp3 (E-Bioscience). Stained cells were analyzed with a FACSCalibur flow cytometer (Becton Dickinson, San José, CA).
Statistics
Skin and cardiac graft survival data were plotted using Kaplan Meier survival analysis. Mann-Whitney rank sum test was used to compare the rank order of the extent of acute rejection changes and the proportion of arteriola with chronic vasculopathy in different treatment groups. A P value of Ͻ0.05 was considered to be significant.
RESULTS
Skin Transplantation Following Primary Heart Transplantation Induces Rejection
C57BL/6 mice transplanted with fully major histocompatibility complex (MHC)-mismatched cardiac grafts from BALB/c donors and treated with CTLA4Ig, anti-CD40L, and anti-LFA-1 exhibit indefinite graft survival. Recipients receiving this treatment stably accepted the grafts for Ͼ100 days and had a histological morphology showing a mild lymphocytic infiltrate spread throughout an intact myocardial architecture and with minimal signs of chronic vasculopathy (Table 1) . At 50 days after primary heart transplantation, without any further treatment, three of the nine mice were randomized to transplantation with a secondary skin graft of donor origin. Recipient mice had a delayed skin graft rejection with a median survival time of 30 days (Table 1) . Primary heart transplants continued to contract throughout the observation period but displayed signs of chronic vasculopathy and an increase in lymphocytic infiltration and fibrosis when examined histologically at 100 days after cardiac transplantation.
IL-10 ؊/؊ Recipients Acutely Reject Cardiac Allografts
Suspecting regulatory T cells to be involved in the longterm acceptance of these transplants and recognizing the importance of IL-10 to regulatory T-cell function in other tolerance strategies, we wanted to investigate the role of IL-10 in the induction of tolerance induced by costimulation blockade. We transplanted BALB/c cardiac allografts to IL-10 Ϫ/Ϫ mice bred on C57BL/6 background. These mice were treated with anti-LFA-1, anti-CD40L, CTLA4Ig. Of the 10 IL-10 Ϫ/Ϫ recipients transplanted, seven grafts stopped beating already two days after transplantation, while the other three had graft survival between 42 and 48 days (Table 1, Figure 1 ). Hearts that stopped beating after two days had a massive neutrophilic infiltrate histologically resembling myocardial infarction. Histological examination of the grafts, which were rejected at 42 and 48 days, revealed severe acute lymphocytic rejection and chronic vasculopathy (data not shown).
T-Cell Derived IL-10 Is Not Essential for Graft Acceptance
The absence of IL-10 production in the above recipients seemed to lead to massive postoperative inflammation and myocardial infarction overshadowing the consequences of IL-10 deficiency in tolerance induction by costimulation blockade. To specifically address whether IL-10 produced by CD4 ϩ T cells was necessary for costimulation blockade induced graft acceptance we performed adoptive transfer experiments.
Rag1
Ϫ/Ϫ recipients were transplanted with BALB/c cardiac allografts and 40 -45 days later received an adoptive transfer of either 10ϫ10 6 IL-10 Ϫ/Ϫ or wild-type CD4 ϩ T cells. The recipients received treatment with costimulation blockade or isotype control antibodies starting on the day of cell transfer. With this approach, no graft losses were observed within the first week after Heart grafts transplanted to wild-type or IL10 Ϫ/Ϫ recipients, with or without rechallenge with a secondary, donor-type skin graft 50 days after primary heart transplantation.
cell transfer. Both groups of mice that received costimulation blockade and were reconstituted with either wild-type or IL10 Ϫ/Ϫ CD4 ϩ T cells stably accepted the grafts. The median graft survival time was more than 100 days whereas isotype control treated mice rejected the grafts early (Table 2) .
Long-Term Graft Survival in Recipients of Treg-Depleted CD4
؉ T Cells These results lead us to question whether CD4 ϩ CD25 ϩ Treg cells are necessary for graft acceptance with this treatment regime. Rag1 Ϫ/Ϫ mice were reconstituted with either 10ϫ10 6 unseparated CD4 ϩ or CD25-depleted CD4 ϩ T cells. Recipients received a BALB/c heart transplant 12-48 hr after T-cell reconstitution and were randomized to treatment with costimulation blockade or isotype control antibodies. Among treated mice, 4/4 mice transferred with CD4 ϩ cells and 6/7 mice transferred with CD4 ϩ CD25 Ϫ T cells had a graft survival time of more than 100 days ( Table 2) . Splenocytes from CD4 ϩ CD25 Ϫ T cell reconstituted Rag1 Ϫ/Ϫ recipients with permanent graft acceptance contained a population of CD4 low CD25 ϩ T cells (Fig. 2) , a phenotype characteristic of natural Treg cells (reviewed in [8] 
CD103
Ϫ cells treated with costimulation blockade also had indefinite graft survival, demonstrating that in this system graft tolerance can be induced in CD4
ϩ T cell populations with minimal content of Foxp3 ϩ natural Treg (Table 2) .
Costimulation Blockade Prevents Homeostatic Proliferation of CD4
؉ CD25 ؊ CD103 ؊ T
cells It is well established that CD4
ϩ T cells transferred to immunodeficient mice will divide extensively (reviewed in [30] ). Under these conditions, proliferation may also be induced by exogenous antigens (31, 32) . Hence, the allograft tolerance induced by costimulation blockade in our experiments might therefore at least partially be dependent on interference with expansion of the transferred CD4 ϩ T cells, both of graft-reactive cells and of cells proliferating due to the lymphopenia of the recipient. To address the possibility that blockade interferes with homeostatic proliferation, CFSElabeled CD4 ϩ CD25 Ϫ CD103 Ϫ T cells were adoptively transferred to Rag1 Ϫ/Ϫ mice and randomized to treatment with either costimulation blockade or with isotype control antibodies. The proliferation of CFSE labeled cells was significantly inhibited in mice treated with costimulation blockade, as compared to cells in control animals (Fig. 3A) . Analysis of the absolute number of Ϫ/Ϫ recipients stopped beating after two days. Wild-type controls were accepted for 100 days without signs of rejection (nϭ6). cells in the same mice revealed a reduced number of CD4 ϩ T cells in the costimulation blockade treated group further supporting that proliferation of the transferred cells was inhibited by costimulation blockade in this model (Fig. 3B) .
Histology of Cardiac Allografts
At 100 days after transplantation of Rag1 Ϫ/Ϫ recipients reconstituted with selected T cells, grafts were harvested and prepared for histology. These grafts had mild lymphocyte infiltrates comparable to the results obtained when wild-type C57BL/6 mice were transplanted with a BALB/c heart and receiving costimulation blockade. There were no significant differences in the extent of acute rejection or chronic vasculopathy when comparing the different groups, Rag1 Ϫ/Ϫ recipients reconstituted with CD4 ϩ T cells from IL-10 Ϫ/Ϫ vs. wild type mice, or reconstituted with CD4 ϩ T cells vs.
cells (data not shown). Previous results have demonstrated the presence of Foxp3
ϩ Treg in accepted allografts (16) . Indeed, a fraction of the invading CD45 ϩ leukocytes in cardiac grafts of transplanted C57BL/6 mice demonstrated positive staining for Foxp3 (Fig. 4A) . There was consistently a higher fraction of Foxp3 ϩ leukocytes in recipients treated with costimulation blockade.
Intragraft CD4
؉ Foxp3 ؉ Cells In order to confirm the presence of intragraft CD4 ϩ
Foxp3
ϩ T cells in the transplanted hearts from C57BL/6 recipients, intragraft cells were isolated and analyzed by FACS. At day 10 after transplantation 11% of the CD4 ϩ T cells isolated from isotype control antibody treated hearts expressed Foxp3. A similar fraction of the CD4 ϩ cells from grafts of animals treated with costimulation blockade expressed Foxp3 at day 10. When costimulation blockade treated hearts were examined at 50 days after transplantation, 33% of the CD4 ϩ T cells were Foxp3 ϩ (Fig. 4B ).
DISCUSSION
Blockade of the costimulatory pathways CD40/CD40L, CD28/CTLA4/B7, and ICAM1-3/LFA-1 leads to acceptance of allogeneic cardiac grafts and induced operational tolerance. The rejection of stably accepted grafts induced by a secondary graft of donor origin suggested that potentially graft reactive cells persisted in these animals. The delayed kinetics of secondary skin graft rejection (mean survival time [MST]ϭ30 days) compared to the kinetics of primary skin grafts transplanted to untreated recipients (MSTϭ12 days, data not shown) along with the failure to completely reject primary heart transplants implied that reactivity may have been actively suppressed (Table 1) .
In earlier studies, evidence has been presented that IL-10 is a prerequisite of Treg function in tissue transplantation models (20) . Therefore, we hypothesized that IL-10 deficiency would eliminate Treg function and thereby test the dependency of our costimulation blockade therapy on Treg cells in cardiac allograft recipients. Surprisingly transplantation directly to IL-10 Ϫ/Ϫ mice lead to hyperacute rejection and myocardial infarction in 7 of 10 recipients. In order to specifically test the importance of IL-10 produced by recipient T cells, we utilized an adoptive transfer model. Graft acceptance was not dependent on recipient CD4 ϩ T cell derived IL-10, since recipients that had been reconstituted with CD4 ϩ cells from IL-10 Ϫ/Ϫ mice all showed indefinite graft survival similar to mice reconstituted with wild-type cells. It is possible that IL-10 produced by other cells maybe sufficient to induce tolerance in reactive T cells in this system. This could also explain the discrepancy in outcome between the transfer of IL-10 Ϫ/Ϫ CD4 ϩ T cells and transplantation directly to IL-10 Ϫ/Ϫ mice. The accelerated loss of the majority of cardiac allografts, within two days, is probably due to inflammation and general lack of control of the innate immune system in the absence of IL-10. IL-10 is known to be important not only for the functions of Treg, but also in regulation of neutrophil recruitment, regulation of production of several proinflammatory cytokines by activated monocytes (33-35) , and in de- activation of macrophages (36) . Our results stand in contrast to earlier published data where BALB/c hearts were transplanted to IL-10 Ϫ/Ϫ mice and had a median graft survival of 55 days (37, 38) . The main difference between the two models is the use of distinct combinations of blocking antibodies. We speculate that the immunosuppressive regimen employed in the previous reports (37, 38) might have downmodulated innate immunity to a greater extent thereby decreasing early graft rejection. Although technical failure cannot be completely ruled out as a cause of the rapid graft losses, it is less likely given that technical failure occurs in only a few percent of performed cardiac transplantations in mice in our laboratory.
Recent evidence indicates that the strength of CD40 signaling in macrophages determines the outcome of antigen presentation. Weak CD40 signaling leads to the production of IL-10, which can downregulate naïve T-cell reactivity, whereas strong, sustained CD40 signaling induces IL-12 production and activation of naïve T-cell clones (39) . This adds prudence to the APC being an important source of IL-10 and the determinator of the outcome of immune responses. In earlier transplant models where IL-10 has been shown to be essential to CD4 ϩ CD25 ϩ Treg function, IL-10 was blocked with soluble antibodies, which cannot discriminate if the source of IL-10 is the Treg or the APC (20) . We have demonstrated that costimulation blockade prevents graft rejection by CD4 ϩ T cells depleted of CD4 ϩ CD25 ϩ T cells, which is in concert with the findings of Graca et al. (9) , who showed that the CD4 ϩ
CD25
Ϫ cell population can indeed act regulatory albeit 10 times less effective than its counterpart, the CD25 ϩ cell subpopulation. In the same study, the authors concluded that IL-10 is not necessary for the actions of any of the regulatory cell populations because addition of antibodies against IL-10 did not impair graft survival. 
population, CD103
ϩ cells were also depleted. 
CD25
ϩ T cells in an in vivo experimental setting where tolerance to an allogeneic skin graft was induced with donor specific transfusion and nondeleting anti-CD4 antibodies (19) . Further, nondepleting anti-CD4 has been used to induce tolerance to skin grafts with minor antigen differences (16) ϩ Foxp3 ϩ T cells are present in the accepted grafts in transplanted C57BL/6 mice and that the frequency of these cells increases with time. In analogy with previous results (16, 40) , we therefore propose that the long-term transplant tolerance, after the disappearance of the blocking antibodies, is at least partially dependent on local suppression by intragraft Foxp3 ϩ Treg. CD4 ϩ CD25 Ϫ T cells adoptively transferred to lymphopenic mice will divide extensively (reviewed in [30] ). Part of this expansion is antigen-dependent (31, 32) . A previous report demonstrated that homeostatic proliferation abolished the inhibitory effect of costimulation blockade on cardiac allograft rejection (41) . In that experimental model, costimulation blockade failed to significantly suppress homeostatic proliferation as well. Because we obtained efficient inhibition of allograft rejection in the CD4 ϩ T cell reconstituted lymphopenic mice in our model, it was important to determine whether this correlated with inhibition of homeostatic proliferation or not. We show here that costimulation blockade also significantly inhibited the proliferation of the transferred T cells. The transfer of a distinct CD4
ϩ T cell population and the use of another costimulation blockade protocol in our experiments might explain this difference with the previous report (41) . Interestingly, CTLA4-Ig treatment was previously shown to cause inhibition of homeostatic proliferation of a subpopulation of rapidly dividing CD4 ϩ T cells (42) . In control-treated animals we detected only few slowly dividing CD4 ϩ T cells (Fig. 3) , but importantly about half of the cells in the rapidly dividing population was sensitive to costimulation blockade, in concordance with the previous study (42) . We do not know what distinguishes these cells from those insensitive to the blockade. One would expect that the CD4 ϩ CD25 Ϫ CD103 Ϫ T cells transferred into allografted Rag-deficient mice, would divide both in response to the allograft and due to the lymphopenia of the recipient. We conclude therefore that costimulation blockade in our model may significantly influence graft rejection. This conclusion is supported by the observation that the frequency of infiltrating CD4 ϩ T cells 10 days after transplantation is lower in allografts from mice treated with costimulation blockade, as compared to control-treated animals (Fig. 4B) .
The CD40L-specific antibody used in these experiments, either in combination with rapamycin (43) or allogeneic lymphoid cells (44, 45) , was previously shown to efficiently deplete reactive T cells in transplantation models. In contrast, treatment with the CD40L antibody in animals transplanted with a heart graft failed to detectably delete graft-reactive CD4 ϩ T cells while significantly retarding the rejection of the tissue graft (44) . In the latter case, the anti-CD40L antibody was suggested to induce the development of Treg, even though expansion of preexisting Treg could not be excluded.
It was initially anticipated that CTLA4Ig treatment would induce anergy and transplant tolerance by blocking costimulation through B7.1 and B7.2 (46) . Recent studies have revealed, however, that CTLA4Ig treatment also induces the tryptophan degrading enzyme indoleamine 2, 3-dioxygenase (IDO) in dendritic cells (DCs) (47, 48) , providing another possible mechanism for tolerance induction. Indeed, plasmacytoid DCs, which are a major source of IDO activity (reviewed in [49] ) have been shown to prolong cardiac allograft survival (50) . In analogy with these previous studies, the combination of anti-CD40L and CTLA4Ig used in the experiments within might cause both deletion of transplant-specific T cells and induction/expansion of transplant-specific Treg.
In conclusion, our results show that a state of operational tolerance is induced by the combined treatment with CTLA4Ig, anti-LFA-1 and anti-CD40L in mice receiving a fully MHC-mismatched, vascularized heart transplant. This state can be established in recipients of CD4 ϩ T cells depleted of Foxp3 ϩ Treg and it does not require T-cell derived IL-10. We propose two possible mechanisms of tolerance in this model. First, costimulation blockade partially inhibits T-cell proliferation, which may limit the number of graft reactive T cells. Second, intragraft Foxp3 ϩ CD4 ϩ T cells may locally suppress antigraft reactivity and prevent rejection.
